SPINE
Recombinant human bone morphogenetic protein-7 ineffective in spinal fusion vs. control
This report has been verified
by one or more authors of the
original publication.
Global Spine J. 2016 Mar;6(2):124-32
6 studies with 442 patients were included in this analysis which was conducted in order to determine if recombinant human bone morphogenetic protein-7 (rhBMP-7) was safe and effective in promoting bone formation in spinal fusion. The findings of this study question the clinical relevance of this treatment as comparable rates of union, complications, postoperative back and leg pain, and revision were reported between rhBMP-7 and control groups. One case of a new onset of cancer was also reported in the rhMBP-7 group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
